Patients often ask why the first months of medically supervised weight treatment feel like a slow ramp. The answer lies in gut physiology, receptor adaptation, and safety data, not clinic caution for its own sake.
July 27, 2026 · Jonas Whitlock
Slowed gastric emptying is the mechanism behind most of what a GLP-1 does to appetite, and it is the same mechanism that changes how every pill you swallow gets absorbed. For most drugs that does not matter. For a specific short list, it does.
July 26, 2026 · Maeve Castellucci
Rapid weight loss on GLP-1 medications can take muscle along with fat. Here is what the physiology says, and what supervised programs actually do about it.
July 24, 2026 · Jonas Whitlock
The full file
60 stories
Side EffectsThe trial data does contain a real answer, and it is not the one most patients are given. Nausea has a median duration of 8 days. Constipation has a median duration of 47. And the worst week for most people is not week one, it is around week 20.
· Nadia Thorvaldsen
ExplainerPatients often judge a medication in the first four weeks, which is exactly when it is not yet doing its full job. Here is what titration actually is, why clinicians insist on it, and what a stalled or rushed schedule can cost you.
· Jonas Whitlock
ExplainerThe biology of discontinuation is predictable, not mysterious. Here is what the data show about appetite rebound, weight regain, and how supervised programs plan for the off-ramp.
· Jonas Whitlock
Myth CheckRoughly a quarter to a third of weight lost on medications like semaglutide and tirzepatide is lean mass. Here is what that number actually means, why it is not automatically alarming, and what supervised programs do about it.
· Kavya Brandstrom
ExplainerAlmost everyone on semaglutide or tirzepatide eventually stops losing weight. The plateau is not a failure of willpower or the drug. It is predictable physiology, and supervised programs plan for it.
· Jonas Whitlock
Side EffectsMost patients settle into one favorite spot on the abdomen within a month and never leave it. The diabetes world learned what happens next about thirty years ago, and the weight management world is largely repeating the lesson from scratch.
· Nadia Thorvaldsen
Common questions
GLP-1 receptor agonists (semaglutide, tirzepatide) mimic gut hormones that signal satiety, slow gastric emptying, and modulate insulin response. Patients typically experience reduced appetite and food noise. Published trials show 15-20%+ body weight loss with sustained use.
The Briefing
A short, occasional dispatch on medically supervised weight solutions, new research, treatment advances, and the stories worth your time. No spam, unsubscribe anytime.
